[{"address1": "200-3650 Gilmore Way", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 316, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 48, "title": "Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1184288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 56, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 682252, "exercisedValue": 0, "unexercisedValue": 436894}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 774702, "exercisedValue": 0, "unexercisedValue": 4053263}, {"maxAge": 1, "name": "Dr. Matthew D. Ronsheim Ph.D.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McClCoskey B.A.", "age": 64, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 63, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 63, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darren S. Cline M.B.A.", "age": 60, "title": "Chief Commercial Officer and Member of Executive Team", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 38.6, "open": 38.57, "dayLow": 38.09, "dayHigh": 38.99, "regularMarketPreviousClose": 38.6, "regularMarketOpen": 38.57, "regularMarketDayLow": 38.09, "regularMarketDayHigh": 38.99, "payoutRatio": 0.0, "beta": 1.165, "forwardPE": -10.873595, "volume": 622075, "regularMarketVolume": 622075, "averageVolume": 1083380, "averageVolume10days": 682580, "averageDailyVolume10Day": 682580, "bid": 38.26, "ask": 39.23, "bidSize": 6, "askSize": 6, "marketCap": 2984765440, "fiftyTwoWeekLow": 26.74, "fiftyTwoWeekHigh": 46.0, "priceToSalesTrailing12Months": 397.96872, "fiftyDayAverage": 33.745, "twoHundredDayAverage": 35.959476, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2505935360, "profitMargins": 0.0, "floatShares": 71595819, "sharesOutstanding": 77105800, "sharesShort": 6892652, "sharesShortPriorMonth": 6505144, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.08939999, "heldPercentInsiders": 0.0014300001, "heldPercentInstitutions": 1.11466, "shortRatio": 6.8, "shortPercentOfFloat": 0.099700004, "impliedSharesOutstanding": 77645104, "bookValue": 8.24, "priceToBook": 4.6978154, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -278228000, "trailingEps": -3.55, "forwardEps": -3.56, "enterpriseToRevenue": 334.125, "enterpriseToEbitda": -7.943, "52WeekChange": -0.035865486, "SandP52WeekChange": 0.16844666, "quoteType": "EQUITY", "currentPrice": 38.71, "targetHighPrice": 65.0, "targetLowPrice": 43.0, "targetMeanPrice": 54.89278, "targetMedianPrice": 55.0, "recommendationMean": 1.21053, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 18, "totalCash": 487544992, "totalCashPerShare": 6.323, "ebitda": -315496000, "totalDebt": 8715000, "quickRatio": 14.786, "currentRatio": 15.138, "totalRevenue": 7500000, "debtToEquity": 1.375, "revenuePerShare": 0.096, "returnOnAssets": -0.25518, "returnOnEquity": -0.37649, "grossProfits": -245127008, "freeCashflow": -149782000, "operatingCashflow": -229935008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -42.416, "financialCurrency": "USD", "symbol": "XENE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Xenon Pharmaceuticals Inc.", "regularMarketChangePercent": 0.284976, "regularMarketPrice": 38.71, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1756498823, "regularMarketTime": 1756497600, "exchange": "NGM", "messageBoardId": "finmb_565718", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekHighChangePercent": -0.15847827, "fiftyTwoWeekChangePercent": -3.5865486, "earningsTimestamp": 1754942400, "earningsTimestampStart": 1762804800, "earningsTimestampEnd": 1762804800, "earningsCallTimestampStart": 1754944200, "earningsCallTimestampEnd": 1754944200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.55, "epsForward": -3.56, "epsCurrentYear": -4.27419, "priceEpsCurrentYear": -9.056686, "fiftyDayAverageChange": 4.965, "fiftyDayAverageChangePercent": 0.14713292, "twoHundredDayAverageChange": 2.7505226, "twoHundredDayAverageChangePercent": 0.07648951, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "longName": "Xenon Pharmaceuticals Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1415197800000, "postMarketChangePercent": 0.0, "postMarketPrice": 38.71, "postMarketChange": 0.0, "regularMarketChange": 0.110001, "regularMarketDayRange": "38.09 - 38.99", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1083380, "fiftyTwoWeekLowChange": 11.969999, "fiftyTwoWeekLowChangePercent": 0.44764397, "fiftyTwoWeekRange": "26.74 - 46.0", "fiftyTwoWeekHighChange": -7.290001, "displayName": "Xenon Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-08-30"}]